van Rij Simon, Dowell Tony, Nacey John
N Z Med J. 2013 Aug 30;126(1381):27-36.
Prostate cancer is the second most common cancer among men in New Zealand. Prostate-specific antigen (PSA) as a screening tool for prostate cancer remains controversial. The aim was to determine the rate of PSA screening in New Zealand and to survey general practitioners' utility of PSA and their attitudes towards PSA screening.
A questionnaire was sent to 1000 general practitioners (GPs). In addition, a non-identifiable prospective audit of all registered New Zealand GPs' laboratory PSA tests was accessed for 2011.
Of the 931,923 males older than 40 years, 267,037 had a PSA test performed (28.3%). This percentage peaked in the 65-75 age group (45%). 263 GP questionnaires were completed. 79% of all GPs would initiate discussion of PSA testing. The most common method of testing was at a time of another health need or check-up.
The incidence of yearly PSA testing in the New Zealand male population over the age of 40 is 28%. GPs provide appropriate information for men to make an informed decision about PSA screening. There is an increasing population of GPs who will not initiate any discussion of PSA testing in their male patients.
前列腺癌是新西兰男性中第二常见的癌症。前列腺特异性抗原（PSA）作为前列腺癌的筛查工具仍存在争议。本研究旨在确定新西兰PSA筛查的比率，并调查全科医生对PSA的使用情况及其对PSA筛查的态度。
向1000名全科医生（GP）发放问卷。此外，获取了2011年对所有新西兰注册全科医生的实验室PSA检测进行的一项不可识别的前瞻性审计数据。
在931923名40岁以上男性中，有267037人进行了PSA检测（28.3%）。这一百分比在65 - 75岁年龄组达到峰值（45%）。共完成263份全科医生问卷。79%的全科医生会主动展开关于PSA检测的讨论。最常见的检测方式是在进行其他健康检查时。
新西兰40岁以上男性每年进行PSA检测的发生率为28%。全科医生为男性提供了适当的信息，以便他们就PSA筛查做出明智的决定。越来越多的全科医生不会主动与男性患者讨论PSA检测。
